REG - Medpal AI PLC - Opening of AI-powered National Distribution Centre

Medpal AIAnnouncement

22/10/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251022:nRSV2951Ea&default-theme=true

RNS Number : 2951E  Medpal AI PLC  22 October 2025

22 October 2025

 

MedPal AI Plc

("MedPal AI" or the "Company")

 

Opening of 24/7 AI-Powered National Distribution Centre

 

Further to its announcement on 1 October 2025 regarding the acquisition of key
assets from Universal Pharmacy Limited (in administration) ("Universal"),
Medpal (AIM:MPAL), is pleased to announce the opening of a distribution centre
at Ecotech Business Park, Swaffham (the "Centre").

 

Included in the assets acquired by the Company's wholly owned subsidiary
Medpal Limited from Universal was a Distance Selling Pharmacy (DSP) licence
enabling nationwide distribution of medication and a warehouse unit at the
Centre. The UK pharmacy regulator, the General Pharmaceutical Council
("GPhC"), ceased issuing new DSP licences in June 2025. Using some of the
proceeds of the placing and retail offer also announced on 1 October 2025,
Medpal Limited has acquired advanced robotic dispensing equipment and
leased two adjacent units, tripling the size of the original facility to
create a state-of-the-art, 24/7 automated medicines fulfilment hub, which
will be integrated with AI to enable the delivery of over 100,000
prescriptions per month.

 

Access to the pharmacy service will be advertised nationally and via the
Company's MedPal app. At any time of day or night, users of the service will
be able to complete an AI-supported consultation, which will produce a
recommendation for a prescription, which will be signed off by a qualified
Independent Prescriber ("IP") or General Practitioner ("GP") and then
fulfilled at the Centre, which, being entirely automated, operates 24 hours a
day. Medication will then be delivered to the user either the same or next
day. There will be no charge to the user for the consultation or prescription,
only for the medication.

 

Highlights

·      Tripled footprint at Ecotech Business Park to support national
scale, resilience and extended hours.

·      Automation-led operations: installation of an Omnicell VBM and
a BD Rowa VMAX advanced robotic dispensing system to increase throughput,
accuracy and cost efficiency.

·      AI-enabled triage: MedPal Limited's AI triage routes users to
appropriate care, with instant access to independent prescribers and GPs,
providing oversight and issuing prescriptions where clinically appropriate.

·      Faster access to treatment: launch of same-day and next-day
delivery services for eligible prescription medicines, including weight-loss
treatments and other therapies, subject to prescription and clinical
suitability.

·      24/7 capability: continuous intake, verification and automated
dispensing to improve service levels for both private and NHS prescriptions.

Revolutionising Primary Care Through AI and Robotics

The Centre brings together MedPal's "digital front door" (including the
MedPal app) and advanced robotic dispensing, delivering a vertically
integrated, low-cost, high-reliability fulfilment model.

 

The expanded facility is designed to:

·      increase access to primary-care pathways by providing rapid
digital assessment and streamlined prescribing;

·      lower unit costs through automation, enabling competitive
pricing and improved patient affordability;

·      enhance safety and quality via barcoded workflows, machine
vision checks and pharmacist oversight; and

·      support growth in both direct-to-consumer private prescriptions
and NHS prescription supply for community patients.

The Centre will initially focus on high-demand services including weight loss
medications, and chronic disease management prescriptions with same-day
delivery capability in key metropolitan areas and next-day delivery
nationwide. The 24/7 operational model addresses the growing demand for
telehealth services, particularly among working-age patients unable to access
traditional GP surgeries during business hours.

 

 

At the heart of this development is the integration of MedPal's proprietary AI
triage system with state-of-the-art robotic dispensing technology, which
leverages AI and robotics to reduce dispensing errors, optimise inventory, and
scale services to meet growing demand. This synergy allows MedPal app users to
access telemedicine and telehealth services, optimising speed and
affordability, making primary care available instantly and affordably,
facilitating better health outcomes than conventional processes where users
frequently encounter accessibility challenges such as delays and/or high
costs.

 

 

 Jason Drummond, CEO of MedPal AI commented:

 

 "This distribution centre represents a milestone in our mission to
democratise healthcare. By combining our Medpal AI triage with robotic
innovation, we are creating a 24/7 ecosystem that makes primary care
accessible and affordable, while always prioritising patient safety through
human expertise and oversight."

 

About MedPal AI

 

MedPal AI is a UK-based digital health company specialising in AI-driven
wellness management. Its core app aggregates data from over 100 wearables and
health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile,
offering non-clinical, personalised lifestyle guidance through its AI wellness
coach. The Company is also developing conversational AI to provide
voice-based, real-time health insights, alerts, and recommendations.

The addition of an AI-driven consumer platform with automated pharmacy
operations to deliver timely, affordable access to medicines and telehealth
pathways across the UK is highly complementary to the MedPal app and in line
with the Company's stated strategy to explore opportunities to expand into
telehealth.

 

 

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for
a limited time, grant exclusive, zero-cost access to the MedPal AI app across
Epassi's network of 11M+ employees at major firms like Siemens and Volvo.
Beyond consumers, MedPal AI plans to expand via B2B licensing to healthcare
providers, businesses, and insurers, with potential use in insurance-linked
wellness programs to reduce premiums and drive new revenue through
institutional partnerships. The Company also has a partnership agreement with
Independent Gyms Ltd.

 

View the link to watch an interview with CEO Jason Drummond giving more
information on the launch of the Centre
(https://editor.voxmarkets.co.uk/cms/article/68f7bedd066d459c83ca94bb)
https://editor.voxmarkets.co.uk/cms/article/68f7bedd066d459c83ca94bb
(https://editor.voxmarkets.co.uk/cms/article/68f7bedd066d459c83ca94bb)

 

 

 

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018). The Directors of the Company take
responsibility for the contents of this announcement.

 

Enquiries:

 

MedPal AI
plc
via Square1 Consulting

Jason Drummond, Chief Executive Officer

 

Cairn Financial Advisers
LLP
+44 20 7213 0880

Louise O'Driscoll/Jo Turner

 

Clear Capital Markets
Limited
+44 20 3869 6080

Bob Roberts/ Nick Josh

 

Square1
Consulting
+44 20 7929 5599

David Bick
                                                +44
7831 381201

 

 

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or
anticipated future events and anticipated results that are forward-looking in
nature and, as a result, are subject to certain risks and uncertainties, such
as general economic, market and business conditions, competition for qualified
staff, the regulatory process and actions, technical issues, new legislation,
uncertainties resulting from potential delays or changes in plans,
uncertainties resulting from working in a new political jurisdiction,
uncertainties regarding the results of exploration, uncertainties regarding
the timing and granting of prospecting rights, uncertainties regarding the
timing and granting of regulatory and other third party consents and
approvals, uncertainties regarding the Company's or any third party's ability
to execute and implement future plans, and the occurrence of unexpected
events.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STRFEFEFFEISEFS



            Copyright 2019 Regulatory News Service, all rights reserved